Literature DB >> 16566813

A re-staging transurethral resection predicts early progression of superficial bladder cancer.

Harry W Herr1, S Machele Donat.   

Abstract

OBJECTIVE: To determine whether pathology on a re-staging transurethral resection (TUR) predicts the early progression of superficial bladder cancer. PATIENTS AND METHODS: In all, 710 patients presenting with multiple superficial bladder cancers were evaluated by re-staging TUR and followed for 5 years. Tumours were classified by stage as confined to mucosa (Ta) or invading submucosa (T1), and by grade (low- or high-grade). Pathology on re-staging TUR was correlated with the endpoints of tumour recurrence and stage progression.
RESULTS: Of the 710 patients, 490 (69%) had a recurrence and 149 (21%) progressed over 5 years. Eighty patients had high-grade invasive (T1G3) cancer on re-staging TUR and 61 (76%) progressed to muscle invasion (median time to progression 15 months), compared with 88 of 630 (14%) who had no evidence of tumour (T0) or other than T1 tumours detected on re-staging TUR.
CONCLUSION: A re-staging TUR identifies patients with superficial bladder cancer who are at high risk of early tumour progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16566813     DOI: 10.1111/j.1464-410X.2006.06145.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  20 in total

1.  Best of the 2006 AUA Annual Meeting: Highlights from the 2006 Annual Meeting of the American Urological Association, May 20-25, 2006, Atlanta, GA.

Authors: 
Journal:  Rev Urol       Date:  2006

2.  Selecting patients for immediate cystectomy.

Authors:  Shahrokh F Shariat
Journal:  Rev Urol       Date:  2007

Review 3.  Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer.

Authors:  Miguel Ramírez-Backhaus; José Domínguez-Escrig; Argimiro Collado; José Rubio-Briones; Eduardo Solsona
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

4.  The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin.

Authors:  Paolo Gontero; Richard Sylvester; Francesca Pisano; Steven Joniau; Marco Oderda; Vincenzo Serretta; Stéphane Larré; Savino Di Stasi; Bas Van Rhijn; Alfred J Witjes; Anne J Grotenhuis; Renzo Colombo; Alberto Briganti; Marek Babjuk; Viktor Soukup; Per-Uno Malmström; Jacques Irani; Nuria Malats; Jack Baniel; Roy Mano; Tommaso Cai; Eugene K Cha; Peter Ardelt; John Vakarakis; Riccardo Bartoletti; Guido Dalbagni; Shahrokh F Shariat; Evanguelos Xylinas; Robert J Karnes; Joan Palou
Journal:  BJU Int       Date:  2015-11-06       Impact factor: 5.588

5.  Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought.

Authors:  J Palou; F Pisano; R Sylvester; S Joniau; V Serretta; S Larré; S Di Stasi; B van Rhijn; A J Witjes; A Grotenhuis; R Colombo; A Briganti; M Babjuk; V Soukup; P U Malmstrom; J Irani; N Malats; J Baniel; R Mano; T Cai; E K Cha; P Ardelt; J Varkarakis; R Bartoletti; G Dalbagni; S F Shariat; E Xylinas; R J Karnes; P Gontero
Journal:  World J Urol       Date:  2018-05-02       Impact factor: 4.226

6.  Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer.

Authors:  H Barton Grossman; Michael A O'Donnell; Michael S Cookson; Richard E Greenberg; Thomas E Keane
Journal:  Rev Urol       Date:  2008

7.  Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1 G3).

Authors:  Richard E Hautmann; Bjoern G Volkmer; Kilian Gust
Journal:  World J Urol       Date:  2009-03-25       Impact factor: 4.226

8.  Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer.

Authors:  Mohamed Bishr; Jean-Baptiste Lattouf; Mathieu Latour; Fred Saad
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

9.  Abnormal expression of multiple proteins predicts cancer-specific mortality in patients with high-grade non-muscle-invasive bladder cancer treated with transurethral resection.

Authors:  Hideyasu Tsumura; Kazumasa Matsumoto; Yuichi Sato; Masaomi Ikeda; Tetsuo Fujita; Takefumi Satoh; Masatsugu Iwamura
Journal:  Mol Clin Oncol       Date:  2013-03-14

10.  The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.

Authors:  John P Sfakianos; Philip H Kim; A Ari Hakimi; Harry W Herr
Journal:  J Urol       Date:  2013-08-20       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.